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Abstract
The main concern of gene therapy is to target the gene of interest to intended cell
tissues for optimizing treatment efficiency. Genetically engineered bacteria have been
developed as shuttle vectors for localized delivery of therapeutics. Their success
depends upon their tropism to target cells and the efficiency of the engaged delivery
system. Bodies of evidence clearly indicate the great potential of recombinant bacteria
in gene therapy, although most of the studies were just looking for proof-of-concept
rather than a ready-to-use final product. This part will provide an overview of our
current understanding of bacteria-based delivery of therapeutic genes and heterolo‐
gous antigens for prophylactic strategies.
Keywords: Recombinant bacteria, Gene delivery, Gene therapy, Immunoprophy‐
laxy
1. Introduction
1.1. Concept of genetically engineered microorganisms as delivery vectors
Although significant progress has been made in physical and chemical methods for gene
delivery, these nonmicrobial strategies still present some drawbacks related to specificity and
efficiency of gene transfer [1–6]. For example, new formulations of lipid nanoparticles have
led to great improvement in gene stability and transfer, yet there remains a lack of a targeting
system that would favor the gene transfer to particular cell tissues [7]. Live avirulent microbial
vectors such as viruses and bacteria are a promising approach for gene delivery that may serve
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to fill in those blanks [8–14]. As such, microbial vectors are able to not only serve as cell factories
for the production of the transgene but also as vehicles that deliver the transgene to specific
cells for which they have a naturally high tropism. Gene transduction with recombinant
viruses is generally based on the use of an expression cassette encompassing a transgene [8–
11], while in bacteria, the classic approach of gene transfer is based on plasmid-encoded genes
[12–14]. The gene of interest must be delivered to the cell’s nucleus to allow an efficient
manufacturing of the corresponding protein. DNA escape from intracellular bacteria to host
cell cytosol may occur following their phagocytosis and lysosomal degradation within the cell.
This is, however, not the case for intracellular bacteria that resist or subvert the phagolysosomal
processing such as Salmonella or Listeria [15,16] and for extracellular bacteria that behave as
commensals within a specific cellular niche. Commensal bacteria might be, however, of
particular interest if the treatment strategy aims at delivering a gene product to targeted cell
tissue through a potent delivery machinery. The delivery system used by avirulent vectors is
therefore a critical point for optimizing the success of any therapy.
2. Bacteria as delivery vectors in gene therapy
Recombinant bacteria are being considered as an in vivo cell factory that could be used for the
delivery of therapeutic genes to target cells. In this process known as “bactofection,” a number
of bacterial species have been developed as delivery vectors for their application in different
therapeutic approaches.
2.1. Attenuated mutant bacteria
The most known bacteria for such purposes are Salmonella typhimurium strains that have
proven to be useful in DNA vaccination approach. The strategy is based on the transformation
of an attenuated strain with a plasmid DNA bearing the gene of interest. It has been shown
that oral administration of such transformants into mice induced a robust immune response
against gene-encoding antigen [17]. This study is the first to describe the possible transfer of
a plasmid DNA from bacteria to host cells resulting in antigen processing and induction of
specific immunity. This DNA vaccination approach has proven to be useful in prophylactic
settings against tumor antigens. In the murine melanoma model, it has been shown that oral
administration of attenuated S. typhimurium harboring gene sequences encoding tumoral
peptide epitopes fused to murine ubiquitin gene could confer protection against tumor growth
through the induction of a type I protective immunity [18]. This strategy of DNA delivery
allowed an optimized antigen processing for vaccine development.
2.2. Naturally occurring nonpathogenic bacteria
The genus Clostridium comprises a group of nonpathogenic species that are strictly anaerobic
and largely distributed in the environment. They are able to produce endospores that can
selectively germinate under hypoxia. Given these characteristics, wild-type Clostridium has
been used to target tumors that are known as poorly oxygenated tissues [19,20]. Various
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experimental studies have reported the usefulness of clostridia in cancer therapy [21–25]. The
injection of either whole Clostridium or spores into tumor tissues resulted in tumor destruction
as a consequence of the multiplication of bacteria within colonized tumors. Subsequently, more
elaborate strategies were developed for the potential use of Clostridium as a carrier to deliver
prodrug converting enzymes into tumor tissues. Following systemic administration of the
prodrug, the latter can be locally activated by the enzyme within tumor tissues, hence
promoting a targeted effect against cancer cells. Therefore, selective exposure of tumor tissues
to the effect of the prodrug is a promising strategy that may have broad applications in clinical
studies. Likewise, recombinant spores of Clostridium or Bacillus subtilis have been used as a
model for surface expression of vaccine antigens. This is based on insertion into chromosomal
DNA of bacteria of the gene of interest which is fused to a gene encoding a spore surface
protein. This stable genetic construction has allowed an efficient assembly and expression of
a variety of fused proteins on the surface of the forming spores. The strategy of recombinant
spores has been mainly tested for the development of mucosal vaccines [26].
Gene therapy in cancer has been also investigated using a food-grade microorganism
Bifidobacterium infantis, which is a nonpathogenic and anaerobic bacterium that can proliferate
in the hypoxic environment of tumor tissues as well. B. infantis has been applied as a gene
delivery system in various cancer models such as bladder cancer including melanoma [27]
thanks to its specific targeting property to the anaerobic environment of tumor cells. This
bacterium has been successfully used for antitumor suicide gene therapy in a murine model
of renal cell carcinoma [27,28]. This strategy is based on the use of the herpes simplex virus
thymidine kinase/ganciclovir system to selectively kill tumor cells. Recombinant bacteria
bearing virus thymidine kinase gene can replicate within tumor tissue and locally express the
enzyme which, in turn, catalyzes the nontoxic precursor ganciclovir to a toxic form resulting
in tumor cell killing through termination of DNA replication.
Lactococcus lactis is another food-grade bacterium that has been engineered for gene therapy
in inflammatory bowel diseases (IBD). As this bacteria tends to naturally colonize the intestinal
epithelium, they were used as vectors for localized delivery of anti-inflammatory mediators.
In murine model of induced colitis, oral administration of recombinant L. lactis expressing
IL-10 [29], IL-27 [30] or anti-TNF nanobody [31] could reduce intestinal inflammation, thereby
offering a safe and reliable strategy for the treatment of IBD.
3. Type III delivery system: A promising strategy for targeting intended
cell tissues
A broad spectrum of pathogenic bacteria (Salmonella, Shigella, Yersinia, Pseudomonas,...) use the
type III secretion system (TTSS) to deliver their effector molecules to the membrane or into the
host cell’s cytosol to subvert the signaling pathways [32,33]. Most of the effector proteins are
produced and stored inside bacteria before their secretion by the TTSS upon contact with host
cells [34]. This elaborate process allows the bacteria to optimize the function of delivered
molecules and, therefore, to resist the host defense mechanisms and proliferate within their
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niche. The potential of TTSS in gene therapy has been investigated in various experimental
models for localized delivery of vaccine antigens or therapeutic molecules.
3.1. Application in immunoprophylaxy
The first attempt in using the TTSS for the delivery of heterologous antigens for vaccine
purposes was performed with attenuated Salmonella. It has been shown that recombinant
Salmonella harboring a heterologous gene from pathogenic microorganisms fused to a
Salmonella effector protein-encoding gene or to a small DNA sequence coding for bacterial
signal peptide was able to deliver the hybrid protein into the host cytosol [35]. When injected
into mice, these recombinant bacteria induced a protective cytotoxic T lymphocyte (CTLs)
response against infection. Thus, the engagement of the hybrid protein by the TTSS allows
their subsequent engagement by the major histocompatibility class-I pathway and generation
of CTLs that are required for effective immunity against intracellular pathogens [36–38]. The
use of the TTSS vaccination approach has been proven to work in different infectious models.
In parasitic models of Plasmodium berghei infection, TTSS-dependent delivery of a dominant
CD8 epitope by Salmonella conferred protection from infection in mice [39]. In a similar way,
Yersinia has been used in vaccination studies in murine models to deliver antigens from a
pathogenic protozoan parasite Entamoeba histolytica [40]. In this model, it has been shown that
TTSS can mediate the delivery of high-molecular-weight antigen that induced significant
protection against infection through promoting specific type 1 immune response.
The experimental approach of the bacterial TTSS in vaccination studies has been investigated
in cancer models as well. Studies in mice indicated that oral administration of recombinant
Salmonella expressing tumor antigens induced CD8+ T cell-mediated control of tumor progres‐
sion [41,42]. Pseudomonas aeruginosa was also evaluated as a live attenuated vector for TTSS
delivery of antigen in antitumor vaccine experiments. Inoculation of recombinant Pseudomo‐
nas delivering ovalbumin to mice was shown to induce specific CD8+ T cell response that was
associated with a significant resistance against ovalbumin-expressing tumor [43]. These
experimental investigations underline the efficacy of this delivery system in antitumor
immunoprophylaxy.
Besides their role in the delivery of heterologous antigens, bacterial vectors present major
advantages over nonmicrobial adjuvant vaccines in that they are endowed with the ability to
induce innate immunity through pathogen-associated molecular patterns (PAMPs). These
specific microbial motifs include lipoproteins, lipopolysaccharides, single-strand RNA, and
nonmethylated DNA sequences that can trigger the maturation process of antigen-presenting
cells through binding to their specific Toll-like receptors and consequently induce the pro‐
duction of inflammatory cytokines [44]. This is particularly interesting for vaccination
strategies aiming to optimize the protection efficacy [45].
3.2. Application in therapeutic development
Optimal efficiency of any microbial vector in gene therapy relies particularly on its ability to
deliver a sufficient amount of the drug to targeted cell tissues while preserving healthy tissue.
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The fact that Shigella specifically colonizes the colon and activates the TTSS upon contact with
epithelial cells prompted their use as a candidate for localized delivery of anti-inflammatory
mediators in inflammatory bowel diseases. Ulcerative colitis and Crohn’s disease are charac‐
terized by the massive production of inflammatory cytokines such as TNF-α and IL-1β that
mediate colon tissue destruction. Anti-inflammatory recombinant IL-10 was used successfully
for treatment of IBD, although high doses and repeated administrations were necessary for
minimal therapeutic efficacy [46–50]. Bacteria TTSS-mediated delivery of IL-10 may offer a
good alternative of treatment targeting the colon. The proof-of-principle of this strategy was
shown in inflammatory models of Shigella infection. When IL-10 was fused to a bacterial signal
peptide, the hybrid protein was shown not only to be delivered by the TTSS of Shigella but also
to be biologically active. Injection of IL-10 recombinant Shigella to mice induced a marked
reduction of inflammatory symptoms as compared to wild-type Shigella and this was associ‐
ated with a significant local reduction of TNF-α, a major inflammatory cytokine [51]. IL-1
receptor antagonist is a natural inhibitor that antagonizes the inflammatory potential of IL-1β.
Imbalance between IL-1β and IL-1 receptor antagonist is associated with acute intestinal
inflammation [52,53]. In keeping with this, it has been shown that delivery of recombinant IL-1
receptor antagonist in the intestine blocks IL-1β-mediated colitis in rabbits [54]. Localized
delivery of IL-1 receptor antagonist by the TTSS of Shigella was shown to be as efficient as IL-10
in reducing the inflammatory symptoms within invaded tissues [51]. As outlined elsewhere,
the treatment of experimental colitis could be partially achieved using IL-10 recombinant
Lactobacillus that colonizes all the intestine. Nevertheless, Shigella may provide a useful
alternative as a live vector thanks to its specific targeting to the site of IBD, the colon. Yet, due
to safety concerns, this is possible only with the use of highly attenuated Shigella that can be
biologically contained [55]. Furthermore, the efficiency of such an approach awaits additional
insight into experimental intestinal models of Shigella [56,57]. Taken together, the use of
bacterial TTSS for localized delivery of immunogenic antigens or therapeutic molecules may
offer alternative options in improving the effectiveness of gene therapy.
4. Issues to overcome for better translating the generated proofs-of-concept
to effective treatments in human
Bodies of evidence clearly indicate that bacterial vectors are a promising strategy for gene
delivery. Many experimental investigations have shown proof-of-concept examples of the
feasibility of such an approach, yet steps forward are still needed not only to translate these
concepts into effective treatments for humans but also to find the perfect delivery system for
each disease situation.
For safety reasons, nonpathogenic food-grade bacteria remain more attractive as live vectors
for vaccine and therapeutic strategies. Some concerns exist, however, about targeting issues
which is crucial for optimal efficiency. The best example is the potential use of Lactobacillus
lactis for the delivery of IL-10 in the treatment of IBD. As this anti-inflammatory cytokine has
a pleiotropic immunosuppressive effect, it is particularly crucial to target the inflammatory
site while preserving healthy tissues. On the other hand, studies related to the potential
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application of some microbial vectors in gene therapy are on hold for safety issues. Although
research on attenuated bacteria has led to significant progresses in gene therapy, there remain
some limitations that preclude their use in immunocompromised populations as well as in
infants. The challenge is how to emphasize the benefits while controlling the disadvantages
of these microbial vectors. With this regard, recent studies highlighted new lines of develop‐
ment of TTSS-based delivery in avirulent vectors. Interestingly, the gene locus coding for TTSS
of Vibrio parahaemolyticus has been cloned into a nonpathogenic E. coli K-12 strain and shown
to be efficient in the delivery of heterologous peptides. The generation of a nonpathogenic E.
coli displaying an active TTSS is an important step that opens the way for applicability of TTSS-
dependent delivery of foreign molecules [58]. In the same way, it has been shown that bacterial
minicells derived from aberrant cell division of a mutant strain of S. typhimurium may assemble
functional TTSS. These nonreplicating nanoparticles were shown to deliver antigen by the
TTSS and to promote Th1 immune response, thereby offering an alternative strategy of antigen
delivery platform for vaccine and immunotherapeutic developments [59].
5. Perspectives
Recombinant bacteria have shown great potential in the preclinical trials. Their clinical
potential relies on their safety and biological containment. Most of the studies were just looking
for proof-of-concept rather than a final product that could be put directly to use. Given the
global needs, future research challenges should focus on the balance between the optimization
of gene therapy through effectiveness of gene delivery to target cells and the biological control
of recombinant bacteria to ensure not only an appropriate shutoff mechanism but also to
minimize the risks of insertional mutagenesis and aberrant genomic location of delivered
genes.
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